TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06770426
Drug: phenylephrine
Normalized name: Phenylephrine
DrugBank: Phenylephrine (DB00388)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All patients will recevive phenyleprhine to increase blood pressure. Start phenylephrine with 0.5 mg/hr and titrate upto 3.5 mg/hr or systolic blod pressure 200 mmHg.
Study: NCT06771063
Drug: fluconazole capsules/placebo
DrugBank: Fluconazole (DB00196)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administer fluconazole capsules/placebo orally
Study: NCT06770439
Drug: Gemcitabine+Albumin-bound paclitaxel
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Gemcitabine+ Albumin-bound paclitaxel is one of the recommended first line regime for advanced pancreatic cancer
Study: NCT06774222
Drug: Fruquintinib
Normalized name: fruquintinib
DrugBank: Fruquintinib (DB11679)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fruquinitinib: Take 4 mg QD for 2 weeks and stop for 1 week, every 3 weeks for a cycle; Standard chemotherapy: The selection of drugs is recommended by the 2024CSCO Guidelines for the Diagnosis and Treatment of Gastric Cancer, including SOX, XLOX or S-1, and the treatment cycle is one every 3 weeks
Study: NCT06770270
Drug: Pucotenlimab
Normalized name: Pucotenlimab
DrugBank: Pucotenlimab (DB17552)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pucotenlimab combined with long-course concurrent chemoradiotherapy, followed by two cycles of pucotenlimab combined with CAPOX, and then based on tumor response, TME surgery or a watch and wait strategy will be adopted.
Study: NCT06771609
Drug: Adebry single antibody + VEX metronomic chemotherapy + radiotherapy
Normalized name: Adbry
DrugBank: Tralokinumab (DB12169)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 1、Adebry antibody: 1200mg on day 1, every 3 weeks； 2、VEX Metronomic Chemotherapy: Vinorelbine 20mg orally, once every other day, Q3W Cyclophosphamide 50mg orally, once daily, Q3W Capecitabine 500mg orally, three times daily, Q3W
Study: NCT06771609
Drug: debry single antibody + VEX metronomic chemotherapy
Normalized name: digoxin antibodies Fab fragments
DrugBank: Digoxin (DB00390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1、Adebry antibody: 1200mg on day 1, every 3 weeks； 2、VEX Metronomic Chemotherapy: Vinorelbine 20mg orally, once every other day, Q3W Cyclophosphamide 50mg orally, once daily, Q3W Capecitabine 500mg orally, three times daily, Q3W
Study: NCT06759610
Drug: Tetracyclin
Normalized name: Tetracyclin
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: to evaluate the effect of tetracycline socked pack on acceleration of healing during marsupialization as a primary treatment for locally invasive lesions.
Study: NCT06762119
Drug: CAR-T cell
Normalized name: SynKIR-meso CAR-T cells
DrugBank: SynKIR-110 (DB17365)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAR-T cell
Study: NCT06760156
Drug: Tafasitamab
Normalized name: Tafasitamab
DrugBank: Tafasitamab (DB15044)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: The recommended dose of tafasitamab is 12 mg/kg.
Study: NCT06760156
Drug: Lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: The starting dose for lenalidomide will be 25 mg PO daily.
Study: NCT05210192
Drug: Lidocaine Hydrochloride 1% Solution for Injection_#2
Normalized name: Lidocaine Hydrochloride 1% Solution for injection_#2
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Injection into the sphenopalatine ganglion of the patients in both groups will be made by entering the arcus zygomaticum and oriented at a 45 degree angle towards the opposite tooth. Injections will be made with a dental injector. The first group will be injected with 4ml of 1% lidocaine. Injections will be repeated weekly for the first 4 weeks, then monthly. At the end of the 1st and 3rd months of the treatment, the patients will be evaluated in the routine outpatient clinic control, and the two groups will be compared statistically by questioning the frequency of pain, the number of attacks, the severity of pain (VAS), and the duration of pain.
Study: NCT05573958
Drug: Rivaroxaban 2.5 Mg Oral Tablet
Normalized name: rivaroxaban 2.5 MG Oral Tablet
DrugBank: Rivaroxaban (DB06228)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rivaroxaban 2.5 mg oral tablet will be administered twice daily
Study: NCT05573958
Drug: Clopidogrel tablet
Normalized name: Clopidogrel Tablets
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Clopidogrel 75 mg once daily orally
Study: NCT05573958
Drug: Aspirin tablet
Normalized name: Aspirin Tablets
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin 81 mg tablet once daily
Study: NCT04873570
Drug: Moxifloxacin 400mg
Normalized name: moxifloxacin 400 MG
DrugBank: Moxifloxacin (DB00218)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Moxifloxacin 400mg IR tablet
Study: NCT06666491
Drug: Tafenoquine
Normalized name: tafenoquine
DrugBank: Tafenoquine (DB06608)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A single dose of TQ will be administered orally on Day 1 or Day 2.
Study: NCT06666491
Drug: Primaquine
Normalized name: Primaquine
DrugBank: Primaquine (DB01087)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A single dose of PQ will be administered orally, daily, on Day 1 or 2 to Day 14 (or Day 15 if PQ started on Day 2).
Study: NCT06666491
Drug: Chloroquine
Normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A single dose of CQ will be administered orally, daily, on Days 1 to 3.
Study: NCT06669650
Drug: Oxycodone
Normalized name: Oxycodone
DrugBank: Oxycodone (DB00497)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: oxycodone
Study: NCT06669650
Drug: Hydromorphone
Normalized name: Hydromorphone
DrugBank: Hydromorphone (DB00327)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: hydromorphone
Study: NCT06766201
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Metformin mixed with propylene glycol
Study: NCT06767046
Drug: KRAS-specific Autologous TCR-T cell injection
Normalized name: Autologous bi-epitope BCMA-targeted CAR T-cells
DrugBank: Ciltacabtagene autoleucel (DB16738)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug1 : Fludarabine + Cyclophosphamide Drug2 :Interleukin 2 Drug3 :KRAS-specific Autologous TCR-T cell injection
Study: NCT06769971
Drug: Ivonescimab
Normalized name: Ivonescimab
DrugBank: Ivonescimab (DB18931)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20mg/kg，IV infusion，Day1，Q3W
Study: NCT06769971
Drug: Cadonilimab
Normalized name: Cadonilimab
DrugBank: Cadonilimab (DB16680)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10mg/kg，IV infusion，Day8，Q6W
Study: NCT06769971
Drug: Etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 100mg/kg，IV infusion，Day1-3，Q3W
Study: NCT06769971
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: AUC 5，IV infusion，Day1，Q3W
Study: NCT06767306
Drug: Immunotherapy alone
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: All patients will receive standard of care 1st line immunotherapy as decided by the treating clinician and in accordance with the current listing on the Australian Register of Therapeutic Goods (ARTG) or applicable international regulatory agency.
Study: NCT06763783
Drug: Shingrix
Normalized name: Shingrix
DrugBank: Varicella zoster vaccine (recombinant) (DB13924)
Approvals — FDA: no, EMA: no, PMDA: no
Description: all participants vaccinates with two doses of Shingrix vaccine
Study: NCT06763783
Drug: vaccination with 2 doses of Shingrix vaccine
Normalized name: varicella zoster virus glycoprotein E
DrugBank: Rice (DB10563)
Approvals — FDA: no, EMA: no, PMDA: no
Description: all participants will receive vaccination with 2 doses of Shingrix vaccine. The response to caccine will be compared bitween patients treated with immunosupressive drugs and these not receiving immunosuppresive treatment
Study: NCT06781125
Drug: JCXH-211 Intratumoral Injection Combined with Anti-PD-1 Antibody IV infusion
Normalized name: Monoclonal antibody anti-SSEA-1
DrugBank: Fanolesomab (DB14211)
Approvals — FDA: no, EMA: no, PMDA: no
Description: JCXH-211:Tumor lesions are selected for intratumoral injection, and target or non-target lesions can be selected. The number of lesions selected for injection will be at the investigator 's discretion based on the patient' s general condition and tolerability .~Anti-PD-1 antibody:Dosage and administration according to the instructions.
Study: NCT06669143
Drug: Zanubrutinib
Normalized name: Zanubrutinib
DrugBank: Zanubrutinib (DB15035)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 160 mg bid, po, day 1-21, a maximum of 2 years.
Study: NCT06669143
Drug: Lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 25 mg qd, po, day 1-10, a maximum of 2 years.
Study: NCT06779890
Drug: Sevoflurane
Normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sevoflurane will be administered at concentrations maintaining MAC= 0.8 for the first 60 minutes , MAC=1.2 for the next 60 minutes and MAC= 0.8 until surgery completion.
Study: NCT06779890
Drug: Desflurane
Normalized name: Desflurane
DrugBank: Desflurane (DB01189)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Desflurane will be administered at concentrations maintaining MAC= 0.8 for the first 60 minutes , MAC=1.2 for the next 60 minutes and MAC= 0.8 until surgery completion.
Study: NCT06780930
Drug: Vorasidenib
Normalized name: Vorasidenib
DrugBank: Vorasidenib (DB17097)
Approvals — FDA: no, EMA: no, PMDA: no
Description: For oral administration once daily
Study: NCT06780449
Drug: Cagrilintide
Normalized name: Cagrilintide
DrugBank: Cagrilintide (DB18887)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive cagrilintide subcutaneously.
Study: NCT06780449
Drug: Semaglutide
Normalized name: Semaglutide
DrugBank: Semaglutide (DB13928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants will receive semaglutide subcutaneously.
Study: NCT06780449
Drug: Placebo cagrilintide
DrugBank: Cagrilintide (DB18887)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive placebo matched to cagrilintide subcutaneously.
Study: NCT06780449
Drug: Placebo semaglutide
DrugBank: Semaglutide (DB13928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants will receive placebo matched to semaglutide subcutaneously.
Study: NCT04307615
Drug: Oxygen
Normalized name: Oxygen
DrugBank: Oxygen (DB09140)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxygen: 20 min treatment followed by 10 min rest and assessment
Study: NCT05673785
Drug: Brentuximab Vedotin
Normalized name: Brentuximab Vedotin
DrugBank: Brentuximab vedotin (DB08870)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Brentuximab vedotin IV infusion
Study: NCT05673785
Drug: Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisone tablets
Study: NCT05904028
Drug: Intravitreal injections of 6 mg faricimab on a Treat and Extend schedule
Normalized name: faricimab
DrugBank: Faricimab (DB15303)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravitreal injections of 6 mg faricimab on a Treat and Extend schedule
Study: NCT04630730
Drug: Recombinant intravesical BCG (Bacillus Calmette-Guérin VPM1002BC)
Normalized name: BCG, live, Tice strain
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 dose of VPM1002BC, live, 1-19.2 x 108 colony forming units (CFU) on day 1, 8 (+/- 1 day) and 15 (+/- 1 day)
Study: NCT04630730
Drug: Atezolizumab
Normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Neoadjuvant immunotherapy with atezolizumab, 4 cycles 1200 mg fixed dose iv infusion on d1 q3w starting 4-16 weeks after date of surgery
Study: NCT04630730
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy with cisplatin: 4 cycles 70mg/m2 iv infusion on d1 q3w (starting on d22)
Study: NCT04630730
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Neoadjuvant chemotherapy with gemcitabine: 4 cycles 1000 mg/m2 iv infusion on d1 and d8 q3w (starting on d22)
Study: NCT06334016
Drug: Nicotine
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vape active nicotine
Study: NCT06732466
Drug: Chlorhexidine toothpaste
Normalized name: chlorhexidine / sodium fluoride Toothpaste
DrugBank: Chlorhexidine (DB00878)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A toothpaste containing 0.3% chlorhexidine + 3% AmCl
Study: NCT06732466
Drug: Placebo toothpaste without chlorhexidine and AmCl
Normalized name: chlorhexidine / sodium fluoride Toothpaste
DrugBank: Chlorhexidine (DB00878)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Negative Control Group assigned to use a placebo toothpaste without chlorhexidine and AmCl and brushing with a commercially available adult soft bristle toothbrush.
Study: NCT06188767
Drug: Testosterone Undecanoate
Normalized name: Testosterone Undecanoate
DrugBank: Testosterone undecanoate (DB13946)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Following testosterone/placebo injection, participants undergo supervised resistance training for 4 weeks. This period is followed by a washout period with no drug and either continued resistance training or detraining for 16 weeks. Thereafter, another 4-week period with supervised resistance training is commenced, with no drug.
Study: NCT06094881
Drug: Obinutuzumab Injection [Gazyva]
Normalized name: obinutuzumab Injection [Gazyva]
DrugBank: Obinutuzumab (DB08935)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: intravenous Obinutuzumab administration~This study adopts a prospective, single arm, open design method. 60 subjects were enrolled in the study and were treated with CD20 monoclonal antibody (Obinutuzumab: 1000mg) for once.~The first stage is the main research stage (d1-w12), which is the core treatment period. The subjects will receive intravenous infusion of 1000mg Obinutuzumab for once to observe the safety and efficacy during treatment.~The second stage (w12-w48) is the stage of withdrawal from the visit, mainly to observe the safety and continuous efficacy of Obinutuzumab after treatment.
Study: NCT06777238
Drug: GZR18
Normalized name: Grazoprevir
DrugBank: Grazoprevir (DB11575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered SC
Study: NCT06693908
Drug: Vixarelimab
Normalized name: Vixarelimab
DrugBank: Vixarelimab (DB16350)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vixarelimab will be administered as per the schedule specified.
Study: NCT05501054
Drug: Ipilimumab
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given by IV (vein)
Study: NCT05501054
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given by IV (vein)
Study: NCT05501054
Drug: Ciforadenant
Normalized name: Ciforadenant
DrugBank: Ciforadenant (DB16125)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given by PO
Study: NCT06509191
Drug: Intervention 2
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Melatonin 8 mg/day
Study: NCT04100135
Drug: Thienopyridine (clopidogrel or prasugrel)
Normalized name: Phenopyridine
DrugBank: Oxyquinoline (DB11145)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Thienopyridine tablets (clopidogrel or prasugrel) administered for 6 months following device procedure
Study: NCT06759922
Drug: Tab Metformin + Tab Glimepiride
Normalized name: glimepiride Oral Tablet
DrugBank: Glimepiride (DB00222)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tab Metformin 500mg+ Tab Glimepiride 2mg (FDC) once per orally for 90 days.
Study: NCT06759922
Drug: Tab Metformin + Tab Empagliflozin
Normalized name: empagliflozin / metformin Oral Tablet
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Tab Metformin 500mg+Tab Empagliflozin 12.5mg (FDC) once per orally for 90 days.
Study: NCT06759922
Drug: Tab Metformin +Tab Sitagliptin
Normalized name: metformin / sitagliptin Oral Tablet
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Tab Metformin 500mg+Tab Sitagliptin 50mg (FDC) once per orally for 90 days.
Study: NCT06759922
Drug: Tab Metformin + Tab Empagliflozin + Tab Sitagliptin
Normalized name: EMPAGLIFLOZIN/LINAGLIPTIN/METFORMIN
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Tab Metformin 500mg+Tab Empagliflozin 12.5mg (FDC) + Tab Sitagliptin 50mg once per orally for 90 days.
Study: NCT06772558
Drug: Desflurane Inhalation
Normalized name: Desflurane Inhalation Liquid
DrugBank: Desflurane (DB01189)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Anesthesia was maintained with either desflurane, with inhaled concentrations adjusted based on electroencephalogram (EEG) monitoring.
Study: NCT06591468
Drug: Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisone 30-40 mg/day, at 7am in the morning, gradually reduced after 1 month (5mg every 7-14 days) to 5-10 mg for maintenance treatment
Study: NCT06591468
Drug: UDCA (Ursodeoxycholic acid)
Normalized name: UDCA
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 13-15 mg/kg/day
Study: NCT05271409
Drug: Satralizumab
Normalized name: SATRALIZUMAB
DrugBank: Satralizumab (DB15762)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Study drug will be administered by SC injection in the abdominal or femoral region after all other study-related procedures have been performed at a site visit.
Study: NCT06793761
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pembrolizumab 200mg, IV, 3 cycles
Study: NCT06793761
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: cisplatin 75mg/m2, IV, 3 cycles
Study: NCT06793761
Drug: Nab-paclitaxel
Normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nab-paclitaxel 260mg, IV, 3 cycles
Study: NCT05546268
Drug: Oral MRT-2359
Normalized name: monofluorophosphate
DrugBank: MRT-2359 (DB18015)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orally administered tablets of MRT-2359.
Study: NCT05546268
Drug: Oral MRT-2359
Normalized name: monofluorophosphate
DrugBank: MRT-2359 (DB18015)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orally administered tablets of MRT-2359 in conjunction with intramuscular administration of fulvestrant.
Study: NCT05546268
Drug: Oral MRT-2359
Normalized name: monofluorophosphate
DrugBank: MRT-2359 (DB18015)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orally administered tablets of MRT-2359 in conjunction with orally administered enzalutamide.
Study: NCT06772324
Drug: NORSPAN Buprenorphine Transdermal Patchs for Very-low dose group
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Very-low dose group will receive medication on arrival before completing the relevant assessment tests; the very-low dose group will be administered 1/9 of a 5mg buprenorphine transdermal patch and replaced with a 0mg patch before returning home from the examination.
Study: NCT06772324
Drug: NORSPAN Buprenorphine Transdermal Patchs for Lower dose group
Normalized name: buprenorphine Transdermal System
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: The lower dose group will be administered 1/9 of a 5mg buprenorphine transdermal patch.
Study: NCT06772324
Drug: NORSPAN Buprenorphine Transdermal Patchs for higher dose group
Normalized name: buprenorphine Transdermal System
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: The higher dose group will be administered 1/3 of a 5mg buprenorphine transdermal patch.
Study: NCT06140290
Drug: Etrasimod Immediate Release (IR)
Normalized name: Etrasimod
DrugBank: Etrasimod (DB14766)
Approvals — FDA: no, EMA: no, PMDA: no
Description: An immediate release tablet
Study: NCT05493501
Drug: Aumolertinib monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally, once daily as two 55-mg tablets for a total dose of 110 mg.
Study: NCT05493501
Drug: Pemetrexed
Normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Administered by IV Infusion per prescribing information. Maybe be continued as maintenance therapy
Study: NCT05493501
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered by IV Infusion given over 4 fixed cycles (q3wk × 4 cycles) per prescribing information.
Study: NCT05556746
Drug: Bedaquiline
Normalized name: Bedaquiline
DrugBank: Bedaquiline (DB08903)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Daily therapy for 12 weeks
Study: NCT05556746
Drug: Clofazimine
Normalized name: Clofazimine
DrugBank: Clofazimine (DB00845)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Daily therapy for 12 weeks
Study: NCT05556746
Drug: Pyrazinamide
Normalized name: Pyrazinamide
DrugBank: Pyrazinamide (DB00339)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Daily therapy for 12 weeks
Study: NCT05556746
Drug: Delamanid
Normalized name: delamanid
DrugBank: Delamanid (DB11637)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Daily therapy for 12 weeks
Study: NCT05556746
Drug: Rifampin
Normalized name: Rifampin
DrugBank: Rifampin (DB01045)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily therapy for 26 weeks
Study: NCT05556746
Drug: Isoniazid
Normalized name: Isoniazid
DrugBank: Isoniazid (DB00951)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Daily therapy for 26 weeks
Study: NCT05556746
Drug: Ethambutol
Normalized name: Ethambutol
DrugBank: Ethambutol (DB00330)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Daily therapy for 8 weeks
Study: NCT05556746
Drug: Pyrazinamide
Normalized name: Pyrazinamide
DrugBank: Pyrazinamide (DB00339)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Daily therapy for 8 weeks
Study: NCT05493501
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered by IV Infusion given over 4 fixed cycles (q3wk × 4 cycles) per prescribing information.
Study: NCT05493501
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered by IV Infusion given over 4 -6 fixed cycles per prescribing information.
Study: NCT05493501
Drug: Nab paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered by IV Infusion given over 4 fixed cycles per prescribing information.